Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,064,084 papers from all fields of science
Search
Sign In
Create Free Account
lymphokine-activated killer cell therapy
Known as:
LAK cell therapy
, cell therapy, lymphokine-activated killer
, therapy, lymphokine-activated killer cell
The use of lymphokine-activated killer cells in the treatment of any disease or disorder.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Lymphokine-Activated Killer Cells
interleukin-2/lymphokine-activated killer cells
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules.
Yi-Chun Lin
,
Yi-Chun Huang
,
Yu-Shan Wang
,
R. Juang
,
K. Liao
,
R. Chu
Veterinary Immunology and Immunopathology
2010
Corpus ID: 45078381
2004
2004
Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis
K. Bendtzen
,
J. Petersen
,
J. Halkjær‐Kristensen
,
T. Ingemann-Hansen
Rheumatology International
2004
Corpus ID: 28208876
SummaryInterleukin-1 (Il-1)-like activity in biological fluids was measured by their ability to rectify the Il-1-dependent…
Expand
Review
2003
Review
2003
IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses.
T. Habib
,
A. Nelson
,
K. Kaushansky
Journal of Allergy and Clinical Immunology
2003
Corpus ID: 1769633
1999
1999
Neuroleukin mediated differentiation induction of myelogenous leukemia cells.
J. Chiao
,
W. Xu
,
K. Seiter
,
E. Feldman
,
T. Ahmed
Leukemia research : a Forum for Studies on…
1999
Corpus ID: 29234086
Highly Cited
1997
Highly Cited
1997
Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
M. Nalesnik
,
A. Rao
,
+8 authors
T. Starzl
Transplantation
1997
Corpus ID: 6087321
Lymphoreticular malignancies, collectively called posttransplant lymphoproliferative disorders (PTLD), eventually develop in 2-5…
Expand
1996
1996
The conserved lymphokine element-0 in the IL5 promoter binds to a high mobility group-1 protein.
J. Marrugo
,
D. Marsh
,
B. Ghosh
Molecular Immunology
1996
Corpus ID: 36588024
Highly Cited
1995
Highly Cited
1995
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
S. H. Goey
,
A. Eggermont
,
+6 authors
G. Stoter
British Journal of Cancer
1995
Corpus ID: 5923502
Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of…
Expand
1994
1994
NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs.
R. Kilbourn
,
L. Owen-Schaub
,
+5 authors
O. Griffith
Journal of applied physiology
1994
Corpus ID: 20620481
The effects of NG-methyl-L-arginine (L-NMA), an inhibitor of nitric oxide formation, were studied in dogs treated with…
Expand
Highly Cited
1990
Highly Cited
1990
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
J. Clark
,
J. Smith
,
+7 authors
S. Creekmore
Cancer Research
1990
Corpus ID: 13347510
Several groups have described the efficacy of interleukin 2 (IL-2) plus lymphokine-activated killer (LAK) cells in the treatment…
Expand
Highly Cited
1989
Highly Cited
1989
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16…
G. Weil-Hillman
,
P. Fisch
,
A. Prieve
,
J. Sosman
,
J. Hank
,
P. Sondel
Cancer Research
1989
Corpus ID: 21361847
The phenotype and function of lymphocytes from cancer patients treated with repetitive weekly cycles of continuous i.v. infusions…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE